Immediate Impact

50 hit
Sub-graph 1 of 25

Citing Papers

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Hit
Novel strategies to manage CAR-T cell toxicity
2025 Hit
2 intermediate papers

Works of Sylvie Glaisner being referenced

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
2013

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sylvie Glaisner 187 125 117 99 72 17 328
Ivan P. Law 133 0.7× 109 0.9× 94 0.8× 96 1.0× 51 0.7× 15 342
Sabrina Aliberti 177 0.9× 76 0.6× 57 0.5× 83 0.8× 48 0.7× 19 292
Florence Broussais‐Guillaumot 228 1.2× 95 0.8× 57 0.5× 153 1.5× 55 0.8× 14 305
Gerard Donnelly 261 1.4× 105 0.8× 84 0.7× 172 1.7× 68 0.9× 12 353
Olivia Minelli 197 1.1× 102 0.8× 35 0.3× 121 1.2× 99 1.4× 12 325
Gaetana Capobianco 198 1.1× 90 0.7× 68 0.6× 134 1.4× 42 0.6× 21 281
F. Le Marcʼhadour 197 1.1× 121 1.0× 50 0.4× 134 1.4× 39 0.5× 18 339
Laura Cereceda 195 1.0× 84 0.7× 28 0.2× 123 1.2× 52 0.7× 19 260
Anna Ruskova 184 1.0× 93 0.7× 86 0.7× 97 1.0× 63 0.9× 15 281
Marjan Ertault 222 1.2× 84 0.7× 54 0.5× 88 0.9× 51 0.7× 14 306

All Works

Loading papers...

Rankless by CCL
2026